Biotechnology - macitentan


Current filters:


Popular Filters

Actelion's Opsumit significantly reduced risk of morbidity/mortality events


Results of SERAPHIN, the pivotal study with Switzerland-based Actelion's (SIX: ATLN) macitentan (trade…

ActelionBiotechnologymacitentanOpsumitResearchRespiratory and Pulmonary

Actelion filing for EU approval of Opsumit accepted


Switzerland-based Actelion (SIX: ATLN) says that it has submitted a Marketing Authorisation Application…

ActelionBiotechnologyEuropemacitentanOpsumitRegulationRespiratory and Pulmonary

Actelion files for US approval of Opsumit for PAH


Europe's largest biotech company Actelion (SIX: ATLN) said yesterday that it has submitted a New Drug…

ActelionBiotechnologymacitentanNorth AmericaOpsumitRegulationResearchRespiratory and Pulmonary

Actelion post sales dip for first nine months, but back in profit


Switzerland's Actelion (SIX: ATLN) posted financial results for the first nine months of 2012, with product…

ActelionBiotechnologyFinancialmacitentanOpsumitResearchRespiratory and Pulmonaryselexipag

Actelion's macitentan meets primary endpoint in pivotal Phase III PAH study


Europe's largest biotech company, Actelion (SIX: ATLN), says that initial analysis indicates that the…

ActelionBiotechnologymacitentanResearchRespiratory and Pulmonary

Back to top